Verus Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02M Buy
16,842
+31
+0.2% +$1.81K 0.07% 169
2025
Q4
$907K Buy
16,811
+7,213
+75% +$347K 0.06% 177
2025
Q3
$433K Sell
9,598
-212
-2% -$9.9K 0.03% 258
2025
Q2
$454K Buy
9,810
+3,389
+53% +$166K 0.04% 227
2025
Q1
$392K Buy
6,421
+278
+5% +$16.2K 0.04% 240
2024
Q4
$347K Sell
6,143
-188
-3% -$10.5K 0.03% 257
2024
Q3
$328K Sell
6,331
-114
-2% -$5.35K 0.03% 252
2024
Q2
$268K Sell
6,445
-1,147
-15% -$51.3K 0.03% 278
2024
Q1
$412K Buy
7,592
+861
+13% +$43.9K 0.05% 220
2023
Q4
$345K Buy
6,731
+553
+9% +$29K 0.04% 217
2023
Q3
$359K Sell
6,178
-389
-6% -$23.8K 0.05% 203
2023
Q2
$420K Sell
6,567
-320
-5% -$21.5K 0.06% 182
2023
Q1
$477K Sell
6,887
-15
-0.2% -$1.06K 0.07% 158
2022
Q4
$497K Sell
6,902
-36
-0.5% -$2.71K 0.09% 147
2022
Q3
$493K Sell
6,938
-135
-2% -$9.79K 0.09% 147
2022
Q2
$639K Sell
7,073
-1,346
-16% -$103K 0.13% 123
2022
Q1
$645K Buy
+8,419
New +$565K 0.1% 142
2020
Q1
$875K Buy
15,690
+1,046
+7% +$63.9K 0.27% 56
2019
Q4
$940K Buy
+14,644
New +$839K 0.31% 58

Other funds holding BMY

Verus Capital Partners's BMY Position: Q1 2026 in Review

Verus Capital Partners increased its Bristol-Myers Squibb (BMY) stake by 0.18% in Q1 2026, buying an estimated $1.81K and bringing the position to 16,842 shares worth $1.02M. The position accounts for 0.07% of the portfolio, ranked #169.

Verus Capital Partners first reported a position in BMY in Q4 2019 and has held it in 19 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Verus Capital Partners held 16,842 shares of Bristol-Myers Squibb worth $1.02M as of Q1 2026.
  • Verus Capital Partners bought 31 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.81K.
  • Bristol-Myers Squibb made up 0.07% of Verus Capital Partners's portfolio in Q1 2026, its #169 holding.
  • Verus Capital Partners first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 19 quarters since.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Verus Capital Partners's 13F filing for Q1 2026, filed 22 May 2026.